Valrico, FL, United States of America

Mary Newman

USPTO Granted Patents = 5 

Average Co-Inventor Count = 4.0

ph-index = 3

Forward Citations = 32(Granted Patents)


Company Filing History:


Years Active: 2004-2019

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Mary Newman: Innovator in Pharmaceutical Composition

Introduction

Mary Newman is a distinguished inventor based in Valrico, FL (US), known for her significant contributions to the field of pharmaceuticals. With a total of 5 patents, she has made remarkable strides in developing innovative treatments for various medical conditions.

Latest Patents

One of her latest patents is the formulation and use of exo-S-mecamylamine in treatment. This pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, which is substantially free of exo-R-mecamylamine. The formulation is designed to treat a range of medical conditions, including substance addiction, smoking cessation, hypertension, Tourette's Syndrome, cancer, neuropsychiatric disorders, chronic fatigue syndrome, and more. The recommended dosage ranges from about 0.5 mg to about 20 mg, ensuring effective treatment for patients.

Career Highlights

Mary Newman is affiliated with the University of South Florida, where she continues her research and development in pharmaceutical sciences. Her work has garnered attention for its potential to address complex medical issues and improve patient outcomes.

Collaborations

Throughout her career, Mary has collaborated with notable colleagues, including Douglas Shytle and Paul R Sanberg. These partnerships have enhanced her research efforts and contributed to the advancement of her innovative projects.

Conclusion

Mary Newman exemplifies the spirit of innovation in the pharmaceutical industry. Her dedication to developing effective treatments showcases her commitment to improving health and well-being.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…